室上性心动过速患者行射频消融术后发生心血管不良事件的影响因素分析
Analysis of Influencing Factors of Adverse Cardiovascular Events in Patients with Supraventricular Tachycardia after Radiofrequency Ablation
摘要: 目的:分析室上速患者行射频消融术后再发心血管不良事件的相关因素。方法:收集暨南大学第一附属医院心内科2019年6月~2022年7月收治的SVT发作时存在胸痛以及ST段改变的152例患者的临床资料,通过追踪患者诊疗记录、电话随访等方式,对所有出院患者进行至少为期一年的随访,随访的内容主要包括:患者的一般情况;是否发生MACE。比较发生MACE组未发生组两组患者的一般临床资料、血液生化指标。结果:发现行冠脉造影(OR = 2.570, 95% CI 1.205~5.481, p < 0.05)及年龄(OR = 2.570, 95% CI 1.205~5.481, p < 0.05)是发生心血管不良事件的独立影响因素。结论:对于老年SVT患者进行冠脉造影可能会改善其预后。
Abstract: Aim: To analyze the risk factors of recurrent adverse cardiovascular events in patients with superi-or ventricular tachycardia after radiofrequency ablation. Methods: Clinical data of 152 patients with chest pain and ST segment changes during SVT attack admitted to the Department of Cardiology of the First Affiliated Hospital of Jinan University from June 2019 to July 2022 were collected. All dis-charged patients were followed up for at least one year by tracking patient diagnosis and treatment records and telephone follow-up. The contents of follow-up mainly include: the general condition of the patient; whether MACE occurs. The general clinical data and blood biochemical indexes of the two groups with MACE were compared. Results: Coronary angiography (OR = 2.570, 95% CI 1.205~5.481, p < 0.05) and age (OR = 2.570, 95% CI 1.205~5.481, p < 0.05) was an independent risk factor for cardiovascular adverse events. Conclusion: Coronary angiography may improve the prognosis of elderly patients with SVT.
文章引用:范一明, 陈冬冬. 室上性心动过速患者行射频消融术后发生心血管不良事件的影响因素分析[J]. 临床医学进展, 2024, 14(3): 1104-1109. https://doi.org/10.12677/ACM.2024.143816

参考文献

[1] 林祖近, 刘峰, 吴红光, 等. 射频消融术治疗室上性心动过速728例分析[J]. 心脑血管病防治, 2004, 4(1): 28-30.
[2] Yetkin, E., Ozturk, S., Cuglan, B., et al. (2020) Clinical Presentation of Paroxysmal Supraventricular Tachycardia: Evaluation of Usual and Unusual Symptoms. Cardiovascular Endocrinology & Metabolism, 9, 153-158. [Google Scholar] [CrossRef
[3] Arnett, D.K., Blumenthal, R.S., Albert, M.A., et al. (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiolo-gy/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140, e596-e646. [Google Scholar] [CrossRef
[4] 陆燕莉. 冠心病危险因素与冠脉病变程度的相关性及冠心病风险预测列线图的构建与评价[D]: [硕士学位论文]. 杭州: 浙江大学, 2023.
[5] Li, M., Hu, X., Fan, Y., et al. (2016) Hyperuricemia and the Risk for Coronary Heart Disease Morbidity and Mortality a Systematic Review and Dose-Response Meta-Analysis. Scientific Reports, 6, Article No. 19520. [Google Scholar] [CrossRef] [PubMed]
[6] Waring, W.S., Maxwell, S.R. and Webb, D.J. (2002) Uric Acid Concentrations and the Mechanisms of Cardiovascular Disease. European Heart Journal, 23, 1888-1889. [Google Scholar] [CrossRef] [PubMed]
[7] Aggarwal, A., Jennings, C.L., Manning, E., et al. (2023) Platelets at the Ves-sel Wall in Non-Thrombotic Disease. Circulation Research, 132, 775-790. [Google Scholar] [CrossRef
[8] Yan, T., Zhu, S., Xie, C., et al. (2022) Coronary Artery Disease and Atrial Fibrillation: A Bidirectional Mendelian Randomization Study. Journal of Cardiovascular Development and Disease, 9, 69. [Google Scholar] [CrossRef] [PubMed]
[9] 刘波, 王汉伟, 贺行巍, 阿里木江, 徐昶. 阵发性室上性心动过速合并肌钙蛋白升高对冠心病的诊断意义[J]. 内科急危重症杂志, 2018(6): 456-458.
[10] Wolf, P.A., Dawber, T.R., Thomas, H.E., et al. (1978) Epidemiologic Assessment of Chronic Atrial Fibrillation and Risk of Stroke: The Framingham Study. Neurology, 28, 973-977. [Google Scholar] [CrossRef
[11] KRALEV, S., SCHNEIDER, K., LANG, S., et al. (2011) Inci-dence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angi-ography. PLOS ONE, 6, e24964. [Google Scholar] [CrossRef] [PubMed]
[12] Kannel, W.B., Abbott, R.D., Savage, D.D., et al. (1982) Epidemiologic Features of Chronic Atrial Fibrillation: The Framingham Study. The New England Journal of Medicine, 306, 1018-1022. ttps://doi.org/10.1056/NEJM198204293061703
[13] 马韬. 心律失常患者射频消融术同时联合冠状动脉造影术的临床意义[J]. 中国继续医学教育, 2017, 9(11): 133-135.